Consequently, inhibition of interferon gene expression by the STAT1 inhibitor ruxolitinib has been demonstrated as a potential therapeutic approach in preclinical models of pancreatic cancer, with suggested utility in patients with a high interferon gene signature [40]. This evidence concerns the gene STAT1 and familial pancreatic carcinoma.